MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data for the Phase 2 open-label study of ATH-434 (202).
Details are listed below:
Webcast details
AUSTRALIA PARTICIPANTS:
| Date: | Thursday, 25 July 2024 | ||
| Time: | 8:30 a.m. AEST (Sydney/Melbourne) |
UNITED STATES PARTICIPANTS:
| Date: | Wednesday, 24 July 2024 | ||
| Time: | 3:30 p.m. Pacific Time | ||
| 6:30 p.m. Eastern Time |
Register for the Zoom webcast: https://mstfinancial-au.zoom.us/webinar/register/WN_8zfACjD8TqO7SsMcAyxzkg
Registration is required and dial in details will be sent directly upon registration.
Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
This email address is being protected from spambots. You need JavaScript enabled to view it.
+61 450 648 064
U.S.
Remy Bernarda
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 (415) 203-6386
| Last Trade: | US$5.01 |
| Daily Change: | 0.35 7.51 |
| Daily Volume: | 74,546 |
| Market Cap: | US$90.830M |
October 09, 2025 October 02, 2025 September 15, 2025 September 08, 2025 September 02, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
